Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Olav Bergheim

Olav Bergheim is the Founder and Managing Director of Fjord Ventures.  He has around 30 years of experience in creating and managing life sciences companies.  Olav's experience includes almost 20 years of general management at Baxter Healthcare, where he was Corporate Vice President and President of the Cardiovascular Group (now Edwards Life Sciences). Prior to the Cardiovascular Group, Olav was President of Immunotherapy Worldwide; BioTech Europe; and Baxter Germany. After Baxter, Olav joined the venture capital firm Domain Associates, LLC as a General Partner.  While at Domain Associates, LLC Olav created the Company Creation Initiative which led to the formation of several companies.

Olav Bergheim Headquarters Location

26051 Merit Circle Suite 102

Laguna Hills, California, 92653,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Olav Bergheim News

Glaukos Announces Retirement of Olav Bergheim from Board of Directors

Apr 14, 2016

April 14, 2016 04:30 PM Eastern Daylight Time LAGUNA HILLS, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that Olav B. Bergheim, 65, will retire from the company’s board of directors. Mr. Bergheim, who has been a member of the board since he co-founded Glaukos in 1998, will continue to serve as a director until his current term expires at the company’s Annual Meeting on June 2, 2016. “I am extremely proud to have played an integral role in the founding, development and growth of Glaukos, which has brought a disruptive technology to the market, addressing important unmet clinical needs and making a meaningful difference in the lives of glaucoma patients,” said Mr. Bergheim. “With the company well positioned for long-term success, I believe the time has come for me to focus on new opportunities and challenges with Fjord Ventures, a life sciences accelerator.” Glaukos President and Chief Executive Officer Thomas Burns said, “On behalf of the entire Glaukos organization, I am deeply grateful to Olav for his unwavering commitment and years of dedicated service to Glaukos. We have always appreciated his thoughtful guidance and perspective, and wish him all the best in the future.” About Glaukos Glaukos ( www.glaukos.com ) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA. Contacts

Olav Bergheim Investments

1 Investments

Olav Bergheim has made 1 investments. Their latest investment was in Vessix Vascular as part of their Series A on October 10, 2010.

CBI Logo

Olav Bergheim Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/26/2010

Series A

Vessix Vascular

$4.7M

Yes

Date

10/26/2010

Round

Series A

Company

Vessix Vascular

Amount

$4.7M

New?

Yes

Co-Investors

Sources

Olav Bergheim Portfolio Exits

1 Portfolio Exit

Olav Bergheim has 1 portfolio exit. Their latest portfolio exit was Vessix Vascular on November 08, 2012.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2012

Acquired

$99M

2

Date

11/8/2012

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.